Nature Medicine
July 2016, Volume 22 No 7 pp693-705
http://www.nature.com/nm/journal/v22/n6/index.html

.
Editorial
Vouching for access – p693
doi:10.1038/nm.4151
The US Food and Drug Administration’s priority review voucher system for drugs to treat neglected disease has come under scrutiny for lacking preconditions that ensure fair pricing of the products that they aim to usher forward. That loophole needs to be closed.

Commentary
A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation – pp701 – 705
Kayvon Modjarrad, Vasee S Moorthy, Peter Ben Embarek, Maria Van Kerkhove, Jerome Kim & Marie-Paule Kieny
doi:10.1038/nm.4131
As part of the World Health Organization (WHO) R&D Blueprint initiative, leading stakeholders on Middle East respiratory syndrome coronavirus (MERS-CoV) convened to agree on strategic public-health goals and global priority research activities that are needed to combat MERS-CoV.